Afficher la notice abrégée

hal.structure.identifierCentre d'Etudes Nucléaires de Bordeaux Gradignan [CENBG]
dc.contributor.authorANDREY, Dmytrenko
dc.date.created2014-03-31
dc.date.issued2014-03-31
dc.descriptionOTAVA Ltd. offers new Chelator Fragment Library that comprises 575 compounds. The assembled library contains compounds with chelating groups only.
dc.description.abstractEnApproximately half of all proteins contain metal ions in the active site for their biological activity. Metalloproteins are involved in many different cellular functions, such as storage and transport of proteins, enzymes and signal transduction proteins. A number of metalloproteins are associated with diseases ranging from pathogenic infections to cancer and therefore have been considered to be promising targets for drug discovery. Fragment-based lead design (FBLD) is an important strategy for the identification of metalloenzyme inhibitors. Chelators demonstrate binding affinities suitable for FBLD screening and provide a diverse range of molecular platforms which can be used for developing lead compounds. Also, the propensity for chelators to bind metal ions allows better prediction of their probable binding position within a protein active site in the absence of experimental structural data of the complex. OTAVA Ltd. offers new Chelator Fragment Library that comprises 575 compounds. The assembled library contains compounds with chelating groups only. Molecular weight of compounds is less than 300 Da. ClogP, number of rotatable bonds and number of H donors are ≤ 3, number of H acceptors and sum of halogen atoms are ≤ 4. The LogSw values are less than -5, PSA is less than 80. All compounds have at least one ring. This library provides an excellent basis for development of metalloprotein inhibitors. More information about this library you can find at www.otavachemicals.com.
dc.language.isoen
dc.title.enChelator Fragment Library from OTAVA
dc.typeAutre document
dc.subject.halInformatique [cs]/Biotechnologie
dc.subject.halSciences du Vivant [q-bio]/Biotechnologies
hal.identifierhal-00967874
hal.version1
hal.audienceNon spécifiée
dc.subject.itChelator Fragment Library
dc.subject.itFragment-based lead design
dc.subject.itmetalloenzyme inhibitors
dc.subject.itmetalloprotein inhibitors
dc.subject.itcancer
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-00967874v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.date=2014-03-31&rft.au=ANDREY,%20Dmytrenko&rft.genre=unknown


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée